Descrizione del progetto
Una gestione personalizzata a domicilio della malattia renale cronica
I pazienti che soffrono di malattie croniche necessitano di un monitoraggio continuo o sul lungo termine della loro funzione renale che, data la tecnologia coinvolta, viene ancora condotto principalmente negli ospedali. Il progetto CKDSens, finanziato dall’UE, si propone di migliorare l’attuale assistenza sanitaria e offre ai pazienti affetti da malattia renale cronica la possibilità di una gestione personalizzata. Il progetto introduce un’innovativa piattaforma decentrata in grado di eseguire una diagnosi precoce della disfunzione renale grazie al monitoraggio giornaliero e in tempo reale dei principali biomarcatori renali. Attraverso la decentralizzazione dell’analisi dei biomarcatori, i sistemi diagnostici garantiscono una gestione più sostenibile delle risorse, mentre i singoli pazienti possono condurre una vita più attiva pur ricevendo il medesimo trattamento.
Obiettivo
Frequent monitoring of the renal function is required for hundreds of millions of people (90m in the EU): patients suffering from chronic kidney disease (CKD), diabetes and cardiovascular problems. The monitoring of these patients is still mostly done in hospitals, because the technology involved is too specialized to be handled by patients. Some companies offer limited qualitative monitoring in a near-patient care scenario, but quantitative monitoring is still centralized at hospitals. In this market, CDKSens can make a notable difference.
CreatSens, a technology-based company from Spain, is developing a new point-of-care platform for the personalized management of the kidney function. CKDSens aims to improve current healthcare by introducing new synthetic membranes to detect several relevant biomarkers. CKDSens is a low-cost innovation requiring little expertise, ideal in a near-patient care scenario. By decentralizing the biomarkers’ analysis with new diagnostic systems (i.e. moving it from the hospital to the patient’s home), healthcare professionals will waste less time and money on analyses. This helps sustain our healthcare system. Individual patients will be able to lead a more active life, while health inequalities get tackled along the way. Direct stakeholders are pharmaceutical companies, technological healthcare companies and foundations.
CreatSens wants to assess the technological and economic viability in the first 6 months (phase 1), to deliver a feasibility plan for phase 2 where the key steps for CreatSens to grow as a company in the European context will be introduced. CreatSens' 5-year growth plan is focused on selling the technology in 5 EU countries. We foresee 40 M€ turnover in the next 5 years, with the creation of 50 direct jobs and over 100 indirect jobs.
Campo scientifico
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- medical and health sciencesclinical medicineendocrinologydiabetesdiabetic nephropathy
- natural scienceschemical sciencesinorganic chemistryalkali metals
- engineering and technologymedical engineeringdiagnostic imagingcomputed tomography
- medical and health sciencesclinical medicinenephrologykidney diseases
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
43007 TARRAGONA
Spagna
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.